IDEXX Laboratories has a Cash Ratio of 0.48. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for IDEXX Laboratories's Cash Ratio or its related term are showing as below:
IDXX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.09 Med: 0.4 Max: 0.66
Current: 0.48
During the past 13 years, IDEXX Laboratories's highest Cash Ratio was 0.66. The lowest was 0.09. And the median was 0.40.
IDXX's Cash Ratio is ranked worse than 71.67% of 233
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05
vs IDXX: 0.48
IDEXX Laboratories Cash Ratio Historical Data
The historical data trend for IDEXX Laboratories's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IDEXX Laboratories's Cash Ratio
For the Diagnostics & Research subindustry, IDEXX Laboratories's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories's Cash Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cash Ratio distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Cash Ratio falls into.
IDEXX Laboratories Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
IDEXX Laboratories's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (NAS:IDXX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
IDEXX Laboratories Cash Ratio Related Terms
Thank you for viewing the detailed overview of IDEXX Laboratories's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
IDEXX Laboratories (IDEXX Laboratories) Business Description
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IDXX has been successfully added to your 